STUDY RATIONALE

Figure 1. Ligation‑Guided CAR T‑Cell Therapy With the Goal to Reduce Toxicity: CEA‑ and MSLN‑targeting CARs and HLA‑A*02:01 (CTL1) [11].

Figure 2. The Structure of Tumor‑CAR T Cells Expressing a CEA‑ or MSLN‑Targeted Activator and an HLA‑A*02‑Targeted Blocker [12].

Table 1. Frequency of HLA‑A LOH in Advanced Tumors [9,10,13].

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>HLA‑A LOH Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma</td>
<td>16.0% (569)</td>
</tr>
<tr>
<td>Non‑Small Cell Lung Cancer</td>
<td>17.1% (579)</td>
</tr>
</tbody>
</table>

Figure 3. Frequencies of HLA‑A LOH in Advanced Tumors [9,10,13].

Figure 4. The L‑Rip‑Based Inhibitory Receptor (Blocker) Recognizes Additional HLA‑A*02:01 Alleles [14].

Figure 5. Alias Specific Coverage for a Tumor Sample With HLA‑A*02:01 LOH and the Matched Normal Sample [15].

CONCLUSIONS

The authors would like to thank the following:

• The screeners, clinical research coordinators, study nurses, data managers, and...